[
    [
        {
            "time": "2018-12-18",
            "original_text": "Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies",
            "features": {
                "keywords": [
                    "Lilly",
                    "Aduro Biotech",
                    "Research Collaboration",
                    "License Agreement",
                    "Immunotherapies"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "Teva Reports Positive Top-Line Data for Migraine Candidate",
            "features": {
                "keywords": [
                    "Teva",
                    "Positive",
                    "Top-Line Data",
                    "Migraine Candidate"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Teva Reports Positive Top-Line Data for Migraine Candidate",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study",
            "features": {
                "keywords": [
                    "Lilly",
                    "Taltz",
                    "Humira",
                    "Psoriatic Arthritis Study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "iShares Core High Dividend ETF Experiences Big Inflow",
            "features": {
                "keywords": [
                    "iShares",
                    "Core High Dividend ETF",
                    "Big Inflow"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "ETFs"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "iShares Core High Dividend ETF Experiences Big Inflow",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "A Look At The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Intrinsic Value",
                    "NYSE:LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A Look At The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "Health Care Sector Update for 12/18/2018: LXRX, LLY, APHB, JNJ, PFE, ABT, MRK, APHB",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "LXRX",
                    "LLY",
                    "APHB",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 12/18/2018: LXRX, LLY, APHB, JNJ, PFE, ABT, MRK, APHB",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis",
            "features": {
                "keywords": [
                    "Lilly",
                    "Verzenio",
                    "advanced breast cancer",
                    "subgroups",
                    "concerning prognosis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "Darling Dozen - 12 Healthcare IPOs That Didn't Disappoint",
            "features": {
                "keywords": [
                    "Healthcare IPOs",
                    "Darling Dozen",
                    "Didn't Disappoint"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "IPOs"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Darling Dozen - 12 Healthcare IPOs That Didn't Disappoint",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-18",
            "original_text": "Elanco Initiates 2019 Guidance - Quick Facts",
            "features": {
                "keywords": [
                    "Elanco",
                    "2019 Guidance",
                    "Quick Facts"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "veterinary"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Elanco Initiates 2019 Guidance - Quick Facts",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]